Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · IEX Real-Time Price · USD
2.040
+0.110 (5.70%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 8.75, with a low estimate of 7.00 and a high estimate of 11. The average target predicts an increase of 328.92% from the current stock price of 2.04.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2024.
Analyst Ratings
The average analyst rating for CHRS stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +439.22% | Mar 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +537.25% | Mar 14, 2024 |
| Baird | Baird | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +341.18% | Jan 23, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $12 → $8 | Strong Buy | Maintains | $12 → $8 | +292.16% | Jan 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +537.25% | Dec 27, 2023 |
Financial Forecast
Revenue This Year
267.15M
from 257.24M
Increased by 3.85%
Revenue Next Year
364.45M
from 267.15M
Increased by 36.42%
EPS This Year
-0.59
from -2.53
EPS Next Year
0.07
from -0.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 340.2M | 539.4M | 630.0M | 1.1B | 1.2B |
| Avg | 267.2M | 364.5M | 466.0M | 818.0M | 840.3M |
| Low | 202.4M | 274.3M | 333.2M | 619.2M | 630.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 32.2% | 101.9% | 72.9% | 137.8% | 41.2% |
| Avg | 3.9% | 36.4% | 27.9% | 75.5% | 2.7% |
| Low | -21.3% | 2.7% | -8.6% | 32.9% | -22.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.18 | 0.71 | 1.59 | 2.17 | 2.34 |
| Avg | -0.59 | 0.07 | 0.56 | 1.82 | 1.62 |
| Low | -0.86 | -0.56 | 0.07 | 1.46 | 0.92 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 2,022.1% | 285.7% | 29.0% |
| Avg | - | - | 654.3% | 222.2% | -11.0% |
| Low | - | - | -8.2% | 159.1% | -49.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.